Evommune (EVMN) Cash & Equivalents (2024 - 2026)
Evommune (EVMN) posted quarterly Cash & Equivalents of $48.3 million for Q1 2026, up 747.09% year-over-year from $5.7 million in Q1 2025, and up 9.66% quarter-over-quarter from $44.1 million in Q4 2025.
Evommune (EVMN) Cash & Equivalents (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Cash & Equivalents for 3 consecutive years, with $48.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 747.09% year-over-year to $48.3 million; the TTM figure through Mar 2026 stood at $48.3 million (up 747.09% YoY), while the FY2025 annual figure was $44.1 million, up 171.07% from the prior year.
- Cash & Equivalents climbed to $48.3 million in Q1 2026 per EVMN's latest filing, from $44.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $48.3 million in Q1 2026 and bottomed at $5.7 million in Q1 2025.
- Historically, Cash & Equivalents has averaged $26.6 million across 3 years, with a median of $22.5 million in 2024.
- Annual changes were most pronounced in 2025 — Cash & Equivalents jumped 47.79% — and 2026, when it soared 747.09%.
- Evommune's Cash & Equivalents stood at $16.3 million in 2024, then soared by 171.07% to $44.1 million in 2025, then climbed by 9.66% to $48.3 million in 2026.
- Business Quant data shows EVMN's Cash & Equivalents at $48.3 million in Q1 2026, $44.1 million in Q4 2025, and $26.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 60.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.03 Mn |
| Mar 31, 2026 | 48.32 Mn |
| Dec 31, 2025 | 44.06 Mn |
| Sep 30, 2025 | 26.82 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Dec 31, 2024 | 16.26 Mn |
| Sep 30, 2024 | 18.15 Mn |